For US Healthcare Professionals Important Safety Information Full Prescribing Information


Appropriate Dosing of CroFab Achieves Initial and Sustained Control of Envenomation1

Snakebite treatment should be administered as soon as possible in patients with any sign of envenomation (e.g., local, systemic, or hematologic effects) to prevent clinical deterioration.1

Initial and maintenance doses for CroFab

Administer an initial dose of 4-6 vials* and monitor for signs of progression.

  • Administer an additional 4-6 vials if initial control is not achieved ~1 hour after initial dose
  • Once initial control is achieved, administer an additional 2 vials every 6 hours for up to 18 hours (total of 3 doses)
  • Scheduled maintenance dosing reduced the incidence of coagulation abnormalities due to residual venom1

*Initial dose may vary from 4-12 vials based on clinical judgment and severity of envenomation. Dosing is the same in adult and pediatric patients.1

In pre- and postmarketing studies, 67-88% of patients achieved initial control with an initial dose of 4-6 vials when given according to recommended dosing.2,3

Initial Control Requires Addressing All 3 Components of Envenomation1,4

Arresting local effects of envenomation icon


Local Effects

Progression of edema, ecchymosis, and leading edge of local injury has been arrested

Resolving systemic effects of envenomation icon


Systemic Effects
  • Patient is normotensive and stable
  • Neurotoxicity is resolving or improving
  • Nausea, vomiting, dizziness, or tachycardia is resolving
Reducing hematologic effects of envenomation icon


Hematologic Effects

Coagulation abnormalities (e.g., thrombocytopenia, spontaneous bleeding) have normalized or are trending towards normal

Watch Dr. William Banner discuss his approach to dosing antivenom for children.


CroFab Clinical Studies

Review publications about achieving initial control of envenomation with CroFab

View Articles
CroFab reconstitution syringe icon

CroFab is reconstituted in 3 simple steps1

Learn How to Prepare and Administer CroFab
CroFab patient experience icon

Real-world use supports improved outcomes with CroFab1

Hear Real Patient Experiences
CroFab efficacy checkmark icon

CroFab is clinically proven to achieve initial control of envenomation1

Examine the Data

1. CroFab®. Prescribing information. BTG International Inc.; August 2018. 2. Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030-2036. 3. Lavonas EJ, Gerardo CJ, O'Malley G, et al. Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite. Ann Emerg Med. 2004;43(2):200-206. 4. Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011;11:2.